Evidence supporting the use of: Gypenoside
For the health condition: Cirrhosis of the Liver

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Gypenoside, the primary active saponin component derived from Gynostemma pentaphyllum (Jiaogulan), has been investigated for its potential hepatoprotective effects, including for conditions such as liver cirrhosis. Preclinical studies (mostly in animal models) suggest that gypenosides may exert antifibrotic, antioxidative, and anti-inflammatory effects, which could theoretically benefit patients with liver fibrosis or cirrhosis. For example, several rodent studies have shown that gypenosides can reduce liver fibrosis by modulating inflammatory pathways, inhibiting hepatic stellate cell activation, and suppressing oxidative stress. Additionally, some in vitro studies suggest gypenosides may regulate the expression of genes involved in collagen production and matrix remodeling.

However, evidence from human clinical trials is extremely limited. A small number of clinical studies in China have assessed Gynostemma pentaphyllum extracts in chronic liver disease, but these trials are generally low quality, with small sample sizes and methodological limitations. There is currently insufficient high-quality clinical evidence to recommend gypenosides as a standard or adjunctive therapy for cirrhosis. Thus, while the mechanism-based rationale and preclinical data provide some support, the overall evidence is weak (rated 2/5), and further rigorous clinical studies are needed to determine efficacy and safety in humans.

More about Gypenoside
More about Cirrhosis of the Liver

Products containing Gypenoside

We currently have no products on Vitabase that contain this ingredient.